Early biomarkers of renal injury

Congestive Heart Failure

Volumn 16, Issue SUPPL. 1, 2010, Pages

  Cruz, Dinna N ^a,b   Goh, Ching Yan ^a,c   Haase Fielitz, Anja ^d   Ronco, Claudio ^a,b   Haase, Michael ^d  

^a SAN BORTOLO HOSPITAL   (Italy)

^b International Renal Research Institute Vicenza (IRRIV)   (Italy)

^c Selayang Hospital   (Malaysia)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C; FATTY ACID BINDING PROTEIN; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ACUTE CORONARY SYNDROME; CARDIORENAL SYNDROME; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTRAST INDUCED NEPHROPATHY; DISEASE DURATION; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HEART SURGERY; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; SENSITIVITY AND SPECIFICITY; SYNDROME;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; CYSTATIN C; DISEASE PROGRESSION; FATTY ACID-BINDING PROTEINS; HEART FAILURE; HUMANS; INTERLEUKIN-18; LIPOCALINS; MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS; RISK FACTORS; SYNDROME;

EID: 77955163547     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2010.00163.x     Document Type: Review

References (68)

1. Thakar CV, Christianson A, Freyberg R. Incidence and outcomes of acute kidney injury in intensive care units: a Veterans Administration study. Crit Care Med 2009, 37:2552-2558.
2. Ronco C, McCullough P, Anker SD. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010, 31:703-711.
3. Bagshaw SM, Cruz DN, Aspromonte N. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 2010, 25:1406-1416.
4. Soni SS, Ronco C, Katz N, Cruz DN. Early diagnosis of acute kidney injury: the promise of novel biomarkers. Blood Purif 2009, 28:165-174.
5. Kellum JA, Mehta RL, Levin A. Development of a clinical research agenda for acute kidney injury using an international, interdisciplinary, three-step modified Delphi process. Clin J Am Soc Nephrol 2008, 3:887-894.
6. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993, 268:10425-10432.
7. Mori K, Lee HT, Rapoport D. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005, 115:610-621.
8. Mishra J, Mori K, Ma Q. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004, 15:3073-3082.
9. Yang J, Goetz D, Li JY. An iron delivery pathway mediated by a lipocalin. Mol Cell 2002, 10:1045-1056.
10. Mishra J, Ma Q, Prada A. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003, 14:2534-2543.
11. Mishra J, Dent C, Tarabishi R. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365:1231-1238.
12. Wagener G, Jan M, Kim M. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006, 105:485-491.
13. Haase-Fielitz A, Bellomo R, Devarajan P. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery-A prospective cohort study. Crit Care Med 2009, 37:553-560.
14. Bennett M, Dent CL, Ma Q. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008, 3:665-673.
15. Haase M, Bellomo R, Devarajan P. Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg 2009, 88:124-130.
16. Haase M, Bellomo R, Devarajan P. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009, 54:1012-1024.
17. Hirsch R, Dent C, Pfriem H. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007, 22:2089-2095.
18. Malyszko J, Bachorzewska-Gajewska H, Poniatowski B. Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Ren Fail 2009, 31:910-919.
19. Ling W, Zhaohui N, Ben H. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract 2008, 108:c176-c181.
20. Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S. NGAL (neutrophil gelatinase-associated lipocalin) and L-FABP after percutaneous coronary interventions due to unstable angina in patients with normal serum creatinine. Adv Med Sci 2009, 54:221-224.
21. Damman K, van Veldhuisen DJ, Navis G. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008, 10:997-1000.
22. Aghel A, Shrestha K, Mullens W. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail 2010, 16:49-54.
23. Poniatowski B, Malyszko J, Bachorzewska-Gajewska H. Serum neutro-phil gelatinase-associated lipocalin as a marker of renal function in patients with chronic heart failure and coronary artery disease. Kidney Blood Press Res 2009, 32:77-80.
24. Bolignano D, Basile G, Parisi P. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res 2009, 12:7-14.
25. Hemdahl AL, Gabrielsen A, Zhu C. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006, 26:136-142.
26. Yndestad A, Landro L, Ueland T. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009, 30:1229-1236.
27. Zhu J, Yin R, Wu H. Cystatin C as a reliable marker of renal function following heart valve replacement surgery with cardiopulmonary bypass. Clin Chim Acta 2006, 374:116-121.
28. Che M, Xie B, Xue S. Clinical usefulness of novel biomarkers for the detection of acute kidney injury following elective cardiac surgery. Nephron Clin Pract 2010, 115:c66-c72.
29. Koyner JL, Bennett MR, Worcester EM. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int 2008, 74:1059-1069.
30. Rickli H, Benou K, Ammann P. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol 2004, 61:98-102.
31. Kato K, Sato N, Yamamoto T. Valuable markers for contrast-induced nephropathy in patients undergoing cardiac catheterization. Circ J 2008, 72:1499-1505.
32. Patel PC, Ayers CR, Murphy SA. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail 2009, 2:98-104.
33. Gu FF, Lu SZ, Chen YD. Relationship between plasma cathepsin S and cystatin C levels and coronary plaque morphology of mild to moderate lesions: an in vivo study using intravascular ultrasound. Chin Med J (Engl) 2009, 122:2820-2826.
34. Moran A, Katz R, Smith NL. Cystatin C concentration as a predictor of systolic and diastolic heart failure. J Card Fail 2008, 14:19-26.
35. Ix JH, Shlipak MG, Chertow GM. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail 2006, 12:601-607.
36. Taglieri N, Fernandez-Berges DJ, Koenig W. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis 2010, 209:300-305.
37. Kilic T, Oner G, Ural E. Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis 2009, 207:552-558.
38. Derzhko R, Plaksej R, Przewlocka-Kosmala M, Kosmala W. Prediction of left ventricular dysfunction progression in patients with a first ST-elevation myocardial infarction-contribution of cystatin C assessment. Coron Artery Dis 2009, 20:453-461.
39. Campbell CY, Clarke W, Park H. Usefulness of cystatin C and prognosis following admission for acute heart failure. Am J Cardiol 2009, 104:389-392.
40. Tang WH, Van Lente F, Shrestha K. Impact of myocardial function on cystatin C measurements in chronic systolic heart failure. J Card Fail 2008, 14:394-399.
41. Naruse H, Ishii J, Kawai T. Cystatin C in acute heart failure without advanced renal impairment. Am J Med 2009, 122:566-573.
42. Keller T, Messow CM, Lubos E. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J 2009, 30:314-320.
43. Parikh NI, Hwang SJ, Yang Q. Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study). Am J Cardiol 2008, 102:1194-1198.
44. Rifkin DE, Katz R, Chonchol M. Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. Nephrol Dial Transplant 2010, 25:1560-1567.
45. Manzano-Fernandez S, Boronat-Garcia M, Albaladejo-Oton MD. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic peptide and cardiac troponin T in patients with acute heart failure. Am J Cardiol 2009, 103:1753-1759.
46. Garcia Acuna JM, Gonzalez-Babarro E, Grigorian Shamagian L. Cystatin C provides more information than other renal function parameters for stratifying risk in patients with acute coronary syndrome. Rev Esp Cardiol 2009, 62:510-519.
47. Alehagen U, Dahlstrom U, Lindahl TL. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail 2009, 11:354-360.
48. Liangos O, Tighiouart H, Perianayagam MC. Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009, 14:423-431.
49. Han WK, Wagener G, Zhu Y. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2009, 4:873-882.
50. Han WK, Waikar SS, Johnson A. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008, 73:863-869.
51. Parikh CR, Mishra J, Thiessen-Philbrook H. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 2006, 70:199-203.
52. Haase M, Bellomo R, Story D. Urinary interleukin-18 does not predict acute kidney injury after adult cardiac surgery: a prospective observational cohort study. Crit Care 2008, 12:R96.
53. Furtado MV, Rossini AP, Campani RB. Interleukin-18: an independent predictor of cardiovascular events in patients with acute coronary syndrome after 6 months of follow-up. Coron Artery Dis 2009, 20:327-331.
54. Chalikias GK, Tziakas DN, Kaski JC. Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. Int J Cardiol 2007, 117:333-339.
55. Mallat Z, Heymes C, Corbaz A. Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEB J 2004, 18:1752-1754.
56. Chandrasekar B, Mummidi S, Claycomb WC. Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes. J Biol Chem 2005, 280:4553-4567.
57. Youssef AA, Chang LT, Hang CL. Level and value of interleukin-18 in patients with acute myocardial infarction undergoing primary coronary angioplasty. Circ J 2007, 71:703-708.
58. Kawasaki D, Tsujino T, Morimoto S. Plasma interleukin-18 concentration: a novel marker of myocardial ischemia rather than necrosis in humans. Coron Artery Dis 2005, 16:437-441.
59. Mallat Z, Henry P, Fressonnet R. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 2002, 88:467-469.
60. Negishi K, Noiri E, Doi K. Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury. Am J Pathol 2009, 174:1154-1159.
61. Portilla D, Dent C, Sugaya T. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 2008, 73:465-472.
62. Ohta S, Ishimitsu T, Minami J. Effects of intravascular contrast media on urinary excretion of liver fatty acid-binding protein [in Japanese]. Nippon Jinzo Gakkai Shi 2005, 47:437-444.
63. Nakamura T, Sugaya T, Node K. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis 2006, 47:439-444.
64. Liyan C, Jie Z, Xiaozhou H. Prognostic value of combination of heart-type fatty acid-binding protein and ischemia-modified albumin in patients with acute coronary syndromes and normal troponin T values. J Clin Lab Anal 2009, 23:14-18.
65. Fukuda Y, Miura S, Zhang B. Significance of urinary liver-fatty acid-binding protein in cardiac catheterization in patients with coronary artery disease. Intern Med 2009, 48:1731-1737.
66. Ishii J, Ozaki Y, Lu J. Prognostic value of serum concentration of heart-type fatty acid-binding protein relative to cardiac troponin T on admission in the early hours of acute coronary syndrome. Clin Chem 2005, 51:1397-1404.
67. Erlikh AD, Katrukha AG, Trifonov IR. Prognostic significance of heart fatty acid binding protein in patients with non-ST elevation acute coronary syndrome: results of follow-up for twelve months [in Polish]. Kardiologiia 2005, 45:13-21.
68. Goto T, Takase H, Toriyama T. Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure. Heart 2003, 89:1303-1307.